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Abstract 
The European Myeloma Network provides recommendations for the management of the most 
common complications of multiple myeloma. Whole body low-dose computed tomography is 
more sensitive than conventional radiography in depicting osteolytic disease and thus we 
recommend it as the novel standard for the detection of lytic lesions in myeloma (grade 1A). 
Myeloma patients with adequate renal function and bone disease at diagnosis should be 
treated with zoledronic acid or pamidronate (grade 1A). Symptomatic patients without lytic 
lesions on conventional radiography can be treated with zoledronic acid (grade 1B), but its 
advantage is not clear for patients with no bone involvement on computed tomography or 
magnetic resonance imaging. In asymptomatic myeloma, bisphosphonates are not 
recommended (grade 1A). Zoledronic acid should be given continuously, but it is not clear if 
patients who achieve at least a very good partial response benefit from its continuous use 
(grade 1B). Treatment with erythropoietic-stimulating agents may be initiated in patients with 
persistent symptomatic anemia (hemoglobin <10g/dL) in whom other causes of anemia have 
been excluded (grade 1B). Erythropoietic agents should be stopped after 6–8 weeks if no 
adequate hemoglobin response is achieved. For renal impairment, bortezomib-based regimens 
are the current standard of care (grade 1A). For the management of treatment-induced 
peripheral neuropathy, drug modification is needed (grade 1C). Vaccination against influenza 
is recommended; vaccination against streptococcus pneumonia and hemophilus influenza is 
appropriate, but efficacy is not guaranteed due to suboptimal immune response (grade 1C). 
Prophylactic aciclovir (or valacyclovir) is recommended for patients receiving proteasome 
inhibitors, autologous or allogeneic transplantation (grade 1A). 
  
Introduction 
Multiple myeloma (MM) is characterized by bone destruction, anemia, renal and 
immunological impairment. These complications may lead to severe impairment of the 
quality of life of myeloma patients and may deteriorate their life expectancy. Therefore, 
prophylaxis and supportive treatment for osteolytic disease, pain, anemia, renal insufficiency, 
infections, pain, thromboembolic events and peripheral neuropathy are essential for the 
management of myeloma patients. The aim of this paper of the European Myeloma Network 
(EMN) is to provide useful guidelines for the management of the most common myeloma-
related complications. 
Methods 
An interdisciplinary panel of myeloma experts on behalf of the EMN reviewed all published 
randomized clinical studies, guidelines, meta-analyses, systematic reviews, observational 
studies and case reports on the management of complications in MM. The research was 
performed in PubMed and ISI until the 28
th
 August 2014. The Grading of Recommendations 
Assessment Development and Evaluation (GRADE) system was used for the grading of 
recommendations (Table 1). In cases of lack of sufficient data, an expert consensus was used 
to develop recommendations. The paper was circulated among the panel members; initial 
discussion took place at the 6
th
 EMN Trialist meeting (Baveno, Italy, 15
th–16th September 
2013) and the recommendations were approved by the panel members and the participants at 
the 7
th
 EMN Trialist meeting (Baveno, 14
th–15th September 2014). Subsequently, the 
manuscript underwent two-round revisions between the panel members. 
Table 1. Grade recommendations for grading levels of evidence. 
 
Bone disease 
Osteolytic bone disease is one of the most prominent features of myeloma, and is present in 
up to 80% of patients at diagnosis.
1
 Bone destruction leads to skeletal-related events (SREs), 
i.e. vertebral and other pathological fractures, a need for radiotherapy or surgery to the bone 
and/or spinal cord compression. It is mainly due to an increased osteoclastic activity which is 
accompanied by low osteoblastic function.
1
 Bisphosphonates, radiotherapy, balloon 
kyphoplasty and surgery are the main therapies used for the management of bone disease in 
MM. 
  
Imaging for the diagnosis and follow up of myeloma patients 
Skeletal survey based on conventional radiography (WBXR) is currently considered to be the 
standard technique for the detection of lytic lesions in MM patients and is recommended for 
the detection of bone disease in the CRAB criteria that are used for the definition of myeloma 
defining events.
2,3
 However, novel techniques can detect more lytic lesions compared to 
conventional radiography. Whole-body, multi-detector, low-dose computed tomography 
(WBLD-CT) is more sensitive for the detection of lytic lesions in myeloma compared to 
conventional radiography, it is very easy to perform (the examination is performed in 2 min or 
less), it has a more accurate evaluation of areas with instability or at risk of fracture, and is 
superior regarding the planning for radiotherapy or surgical interventions.
4,5
 Similarly, 
positron emission tomography in combination with CT (PET/CT) is superior to conventional 
radiography in the detection of lytic disease, while whole-body magnetic resonance imaging 
(MRI) accurately depicts the marrow involvement in MM patients.
6,7
 We stress that MRI 
depicts bone marrow involvement, while CT and skeletal survey reveals lytic lesions. 
However, there are some issues that need to be clarified when using such sensitive techniques. 
For example, the issue of the importance of the detection of 2 or 3 small lesions of 3–4 mm of 
diameter by WBLD-CT or by MRI or PET/CT in a patient with no CRAB criteria has not yet 
been solved (i.e. whether this patient will develop symptomatic disease earlier than those 
without such lesions). Furthermore, we do not know the prognostic value of the WBCT, i.e. 
what the difference is between an MM patient with 4 lytic lesions detected by conventional 
radiography and another patient with 14 lytic lesions detected by WBLD-CT. Although these 
questions have not been conclusively answered, data so far support the substitution of 
conventional radiography by WBLD-CT for the detection of lytic disease in MM. Positive 
lesions in WBLD-CT are considered those with a diameter of 5 mm or more. 
Regarding the definition of myeloma defining events, there are important studies which 
suggest that asymptomatic patients with more than 1 focal lesions on MRI have a higher risk 
(more than 70% within 2 years) for progression to symptomatic myeloma.
8,9
 These patients 
need to be treated as having symptomatic disease.
10
 Furthermore, MRI correlates with 
survival in myeloma patients.
11
 PET/CT findings have also been correlated with response to 
therapy and survival.
12,13
 Prospective comparisons between MRI and PET/CT in patients with 
asymptomatic disease have not yet been published. In symptomatic patients there is evidence 
that MRI achieves better results than PET/CT in the staging and disease recurrence, while 
PET/CT has shown faster changes in imaging findings than MRI in patients who respond to 
therapy.
14
 However, in the post-treatment setting, MRI may often be false positive because of 
persistent non-viable lesions and thus PET/CT might be more suitable for the determination 
of remission status.
15
 
Recommendation: WBLD-CT is the novel standard procedure for the diagnosis of lytic 
disease in patients with MM (grade 1A). Conventional radiography can also be used if 
WBLD-CT is not available. In asymptomatic patients with no lytic disease in WBLD-CT, 
whole body MRI (or spine and pelvic MRI if WB-MRI is not available) has to be performed 
and in the presence of more than 1 focal lesion the patients are characterized as having 
symptomatic disease that needs therapy (grade 1A). PET/CT may be useful for the better 
definition of complete or stringent complete response (CR or sCR) and for the progression of 
  
the disease (grade 2B). Figure 1 presents the imaging algorithm which is proposed by the 
EMN for use in myeloma-related bone disease. 
 
Figure 1. Algorithm for imaging in multiple myeloma (MM). In the case of spinal cord compression an urgent 
MRI or CT is obligatory in order to assess the better management (radiotherapy or surgery in the cases on the 
presence of bone fracture segments into the spinal canal). In the suspicion of a plasmacytoma a CT of the area 
and a needle biopsy is needed. In the case of myeloma the WBLD-CT (or the standard conventional radiographic 
evaluation of the skeleton if a WBLD-CT is not available) may reveal or not lytic lesions. If lytic lesions are 
present then the patient fulfils the criteria for symptomatic disease and needs systematic therapy. If not, then a 
WB-MRI (or a spinal and pelvic MRI if a WB-MRI is not available) has to be performed. In the presence of 
more than one focal lesion (more than 5 mm of diameter) in MRI the treating physician should treat the patient 
as having symptomatic myeloma. To date data do not justify the initiation of treatment in asymptomatic patients 
with diffuse MRI pattern of marrow involvement 
 
 
 
 
  
Bisphosphonates 
Based on phase III studies, both pamidronate and zoledronic acid (ZA) have been found to 
reduce SREs compared to placebo.
16–18
 There are only three randomized studies comparing 
the effect of two different bisphosphonates (BP) or two different dosages of the same BP. In 
the first study, ZA was as effective as pamidronate in reducing SREs in the era of 
conventional chemotherapy.
18,19
 In the second, two doses of intravenous pamidronate (30 mg 
vs. 90 mg, monthly) had comparable results regarding time to SRE and SRE-free survival 
time.
20
 The major flaw of this study was that it was powered to show differences in quality of 
life and not in SREs.
20
 Finally, the third study, which compared intravenous ZA with oral 
clodronate, found that ZA reduced the SRE risk compared to clodronate in all patients, 
irrespective of the presence of lytic lesions at diagnosis, but furthermore, improved overall 
survival (OS) by ten months in MM patients with lytic lesions at diagnosis.
21,22
 These effects 
continued in patients who received ZA for more than two years.
23
 However, there was no sub-
analysis according to the response status of the patients, and thus it is not clear if the 
continuous use of ZA produces similar results in patients who have achieved a CR, sCR, very 
good partial response (VGPR) or PR. A recent meta-analysis was not able to confirm 
superiority of ZA over pamidronate, but remarkably revealed a survival advantage of ZA 
versus placebo.
24
 This analysis also showed that in order to prevent one SRE, we need to treat 
6–15 MM patients with BP. 
Recommendations: all MM patients with adequate renal function (creatinine clearance >30 
mL/min) and osteolytic disease at diagnosis should be treated with ZA (4 mg, over an at least 
15-min infusion, every 3–4 weeks) or pamidronate (90 mg, in a 2–4-h infusion, every 3–4 
weeks), intravenously, in addition to specific anti-myeloma therapy (grade 1A). Symptomatic 
patients, without bone disease assessed by conventional radiography, can be treated with ZA 
(grade 1B). The advantage is not clear for patients without bone involvement on MRI or 
PET/CT. In asymptomatic MM, BPs are not recommended (grade 1A); in cases of 
osteoporosis or vertebral fractures that are not due to myeloma, bisphosphonates should be 
given in asymptomatic patients with doses as given for osteoporosis (i.e. 5 mg ZA per year). 
ZA should be given continuously (grade 1B). However, it is currently unknown whether 
patients who achieve VGPR or better have benefits from the continuous use of ZA. Regarding 
pamidronate, there are no data to support its continuous use; thus it should be given for two 
years and then at the physician’s discretion (grade 2C). 
Side-effects of bisphosphonates and their management 
Side-effects of intravenous BPs include acute phase reactions, inflammatory reactions at the 
injection site, hypocalcemia, hypophosphatemia, renal impairment (RI) and osteonecrosis of 
the jaw (ONJ).
25–27
 For the prevention of hypocalcemia, all patients under BPs should receive 
calcium and vitamin D3 supplementation (600 mg calcium per day and 400 IU vitamin D3 
per day); interestingly, approximately 60% of myeloma patients are vitamin D-deficient or -
insufficient.
25
 The treating physicians are encouraged to perform vitamin D measurements at 
least once a year and manage their patients accordingly. 
  
RI due to acute tubular damage and deterioration of renal function can be observed with both 
pamidronate and ZA, but the true incidence of this adverse event remains unknown, as RI is 
also a common complication of MM.
21,25,26
 Thus patients with moderate RI need dose 
reductions of ZA, according to the summary of product characteristics of the drug.
25
 
Regarding pamidronate, its elimination is slower when the CrCl is below 30 mL/min.
26
 
ONJ is an uncommon but sometimes severe complication of BP. Retrospective studies 
suggest that ONJ is observed more often with ZA, after dental procedures, and is associated 
with the prolonged administration of the BP.
27
 It seems that the use of preventive dental 
measures leads to the reduction of ONJ incidence.
28
 There are conflicting recommendations 
regarding precautions before dental extraction in patients who are treated with BP. The most 
recent American Dental Association (ADA) recommendations do not support the 
discontinuation of BP in these cases in the absence of any convincing data and because BP 
remain in the bones for years.
29
 However the International Myeloma Working Group 
(IMWG) guidelines suggest the temporary discontinuation of BP for 90 days before and after 
invasive dental procedures.
25
 
Recommendations: for the prevention of hypocalcemia, calcium and vitamin D3 
supplementation should be given in all patients under intravenous BP (grade 1A). The 
treating physicians are encouraged to perform vitamin D measurements at least once a year 
and manage their patients accordingly. Renal function should be closely monitored by 
measuring CrCl, serum electrolytes and urinary albumin in all patients under BP therapy; 
CrCl should be evaluated before the administration of each intravenous infusion (grade 1A). 
Patients with CrCl 30–60 mL/min should receive reduced doses of ZA with no change to 
infusion time (grade 1A), while pamidronate should be given via 4-h infusion (grade 1C). 
Pamidronate and ZA should not be given in patients with CrCl less than 30 mL/min (grade 
1A); alternatively clodronate can be given in patients with a CrCl more than 12 mL/min 
(grade 2C). Treatment with BP should be discontinued if a patient experiences deterioration 
of renal function until CrCl returns to within 10% of base-line values (grade 1B). Patients on 
chronic dialysis without possibility of renal failure reversal should also receive monthly BPs 
(grade 2C); treating physicians should closely monitor these patients due to high risk for 
hypocalcemia. For all other patients on dialysis, BPs should be avoided until their 
independence from dialysis and the reversal of RI to CrCl more than 30 mL/min (grade 2C). 
Before BP administration, patients should have a thorough dental examination and all major 
dental problems (i.e. dental extractions or other traumatic dental procedures) should be 
resolved (grade 2C). In cases of ONJ, BP should be discontinued and can later be re-
administered if ONJ has healed, at the physician’s discretion (grade 2C). 
Denosumab: denosumab has not yet been licensed for myeloma patients. A large phase III 
study comparing denosumab with ZA is ongoing. Denosumab can currently be given in 
myeloma patients only in the rare cases of resistant hypercalcemia to BPs. 
Radiotherapy: radiotherapy is mainly used in the cases of solitary plasmacytoma, 
symptomatic spinal cord compression, extremely painful lytic lesions and for the prevention 
of pathological fractures. For painful osteolytic lesions, a dose of 3000 cGy in 10–15 fractions 
  
is usually adequate. Radiotherapy may cause delays in applying systemic anti-myeloma 
therapies with radiosensitizing drugs, such as anthracyclinse and proteasome inhibitors. 
Balloon kyphoplasty and vertebroplasty: these techniques are mainly used for the 
management of painful vertebral compression fractures, where almost 80% of patients with 
pain, non-responsive to pain killers, experience pain relief.
30
 All recent data, including a 
phase III study and a large meta-analysis, suggest that balloon kyphoplasty is the treatment of 
choice for the reduction of pain due to cancer-related vertebral fractures and is associated with 
reduced rates of cement leakage
30,31
 (grade 1A). 
Surgery: the administration of very effective novel anti-myeloma regimens has reduced the 
need for surgery during the last decade. Currently, surgery should be used in the following 
cases: i) to fix pathological fractures of the long bones; ii) to prevent and restore axial 
skeleton in cases of unstable spinal fractures; and iii) for spinal cord compression with bone 
fragments within the spinal route (grade 2C). 
Anemia 
Anemia, which is usually normochromic and normocytic, is another common complication of 
MM. It is present in approximatley 75% of patients at diagnosis
32,33
 and in almost all patients 
with uncontrolled disease. Several factors contribute to the development of anemia in MM 
patients: the BM infiltration by the myeloma itself leads to reduced numbers of erythroid 
precursors, erythropoietin deficiency (in patients with RI), decreased responsiveness of the 
pro-erythroblasts and CFU-E cells to erythropoietin, impaired iron utilization due to increased 
production of hepcidin because of chronic inflammation, and paraprotein-induced increase of 
the plasma volume.
33
 However, the major cause of anemia in myeloma is the induction of 
apoptosis of erythroblast by myeloma cells.
34
 Furthermore, anti-myeloma therapy and 
radiotherapy can either cause anemia or exacerbate pre-existing anemia.
35
 
Red blood cell transfusions are helpful for patients who need rapid improvement of their 
anemic condition. Moreover, several prospective studies have shown that erythropoiesis-
stimulating agents (ESAs), such as erythropoietin (Epo)-α and β as well as darbepoetin are 
able to increase hemoglobin (Hb) levels by 2 g/dL or more in 60% to 75% of myeloma 
patients with symptomatic anemia. ESAs mainly reduce transfusion requirements and 
improve quality of life.
36–40
 Predictors of response to ESAs include the ratio of observed to 
expected Hb (<0.9) and the preserved BM function, reflected by the platelet counts 
(>150×10
9
/L).
33,38,41
 A systematic review of the use of ESAs in more than 20,000 cancer 
patients confirmed that their use reduced the relative risk of transfusions due to increase of 
erythroid responses, but there was evidence that ESAs increased mortality during ESA 
administration and thus decreased OS.
42
 Although anemia is common in MM patients, no 
clear consensus exists as to the use and impact of ESAs on outcome in MM and randomized 
studies in MM patients are still limited. However, one randomized study (VISTA sub-
analysis) showed no evidence of inferior outcome after ESA treatment, albeit patient numbers 
were very limited and, therefore, statistically under-powered.
43
 The most recent guidelines 
from the American Society of Hematology (ASH) and American Society of Clinical 
Oncology (ASCO) recommend the administration of ESAs at the lowest possible dose to 
  
avoid transfusions. In case of iron deficiency, which is indicated by low transferrin saturation 
(<20%) and/or high numbers of hypochromic red cells (>5%), the iron should be given 
intravenously.
44
 Important side-effects of ESAs include thromboembolic complications, 
hypertension and possibly increased mortality.
42,45
 Here, it is important to stress that 
nowadays, with very effective combination therapies that rapidly control the disease, the 
systematic need of ESAs in myeloma is a subject of debate. 
Recommendations: treatment with ESAs may be initiated in patients with persistent 
symptomatic anemia (usually Hb levels <10 g/dL) in whom other causes of anemia (i.e. iron 
or B12 deficiency, hemolysis, etc.) have been excluded (grade 1B). The standard dose of Epo-
α is 40,000 U/week, of Epo-β 30,000 U/week and of darbepoetin 150 μg/week or 500 μg every 
three weeks. Hb levels should not increase more than 12 g/dL. ESAs should be stopped after 
6–8 weeks if adequate Hb response is not achieved. True or functional iron deficiency during 
treatment with an ESA should be treated with intravenous iron (grade 1A). 
Renal Impairment 
Incidence and assessment of renal impairment 
Mild renal impairment (RI) (estimated glomerular filtration rate [eGFR] <60 mL/min/1.73 
m
2
), if carefully monitored, can be observed in at least 25%–50% of patients during the 
course of their disease.
46
 The pathophysiology of RI in MM is complex and associated with 
various underlying processes. The principal renal mechanism is tubulointerstitial lesions, such 
as cast nephropathy, a direct consequence of the high serum concentration of immunoglobulin 
free light chains (SFLCs; Figure 2), characterized by tubular atrophy and tubular-interstitial 
fibrosis and the most frequent (approx. 90%) form of renal damage.
47–51
 FLCs can also cause 
functional impairment, resulting in Fanconi’s syndrome, characterized by failure of the 
reabsortive capacity of the proximal renal tubules resulting in glucosuria, aminoaciduria, 
hypophosphatemia and hypouricemia.
52
 Moreover, deposition of monoclonal light chains can 
occur in several organs (kidney, heart, liver, small intestine), leading to the development of 
amyloid light chain (AL) amyloidosis or light chain deposition disease (LCDD). A variety of 
other nephrotoxic processes may also contribute to renal damage, including dehydration, 
hypercalcemia, infections, amyloidosis, and concomitant exposure to nephrotoxic 
medications, such as non-steroidal anti-inflammatory drugs.
46,53 
 
  
 
Figure 2. Mechanisms of FLC-induced acute kidney injury. Serum FLCs are primarily cleared by the 
kidneys through glomerular filtration, endocytosed by the proximal tubule cells and degraded within 
lysosomes.50 In MM, the Ig light chains are produced in excess and absorption mechanisms in the proximal 
tubule are overwhelmed. Thus, the excessive light chains reach the distal tubules, where they form tubular 
casts with Tamm-Horsfall protein (THP), subsequently leading to tubular obstruction.51 Additionally, 
excess FLCs can cause direct injury to proximal tubular cells through the induction of pro-inflammatory 
cytokine production and other pathways leading to tubular cell death.52 The very high concentrations of 
FLCs present in the ultrafiltrate of patients with MM can result in direct injury to PTCs. Activation of redox 
pathways occurs, with increased expression of NFκB and MAPK, which in turn leads to the transcription of 
both inflammatory and profibrotic cytokine. In the distal tubules, FLCs can bind to a specific binding 
domain on THPs and co-precipitate to form casts. These casts result in tubular atrophy proximal to the 
cast and lead to progressive interstitial inflammation and fibrosis. CCL2: hemokine (C-C motif) ligand 2; 
CDR: complementarity determining region; FLC: free light chain; IL: interleukin; MAPK: mitogen-activated 
protein kinase; NFκB: nuclear factor κB; PTC: proximal tubule kidneys; TGF-β1: transforming growth 
factor β1; THP: Tamm-Horsfall protein (adapted to Hutchison et al.49). 
 
According to Durie & Salmon staging system, serum creatinine-levels of 2 mg/dL or more 
(sCr) define RI and represent one of the ‘CRAB’ diagnostic criteria for symptomatic MM.54 
However, serum creatinine is not a suitable factor for the reflection of GFR.
54–55
 Therefore 
predictive of GFR equations based on serum creatinine [Cockcroft-Gault equation and the 
  
Modification of Diet in renal Disease (MDRD)] are often used to define the degree of 
RI.
46,55,56
 The IMWG has recommended the use of the MDRD equation for the estimation of 
GFR in MM patients,
56
 and the Kidney Disease Improving Global Outcomes (KDIGO) 
classification for the classification of RI in MM patients.
57
 Recently, the Chronic Kidney 
Disease Epidemiology Collaboration (CKD-EPI) formulas, with or without cystatin C, has 
been used for the accurate detection of manifest RI,
58,59
 and especially the CKD-EPI-cystatin 
C equation seems to provide an independent prognostic value, which needs to be further 
elucidated and formally compared to currently used equations both in newly diagnosed and 
relapsed patients.
58
 The improved prognostic ability and more sensible detection of RI by the 
CDK-EPI compared to the MDRD estimation therefore enlarges the arsenal of eGFR 
formulas and should lead to a broader use of CKD-EPI formulas for the estimation of GFR in 
patients with myeloma.
59,60
 
Supportive care and mechanical approaches 
MM patients with RI at presentation should be considered a medical emergency. Management 
of patients with RI include adequate hydration, urine alkalinization, and treatment off 
hypercalcemia. High fluid intake alone will at best reduce the urine concentration of the 
pathogenic light chains and should be combined with prompt anti-myeloma therapy, including 
agents without nephrotoxic potency. Therapeutic plasma exchange (TPE) has been suggested 
to impact the outcome of the renal failure by promoting rapid reduction in the levels of free 
light chain,
61
 but its role remains controversial.
62
 The largest prospective randomized trial 
performed so far found no impact of TPE on the composite end point of death, dialysis 
dependence, and GFR less than 30 mL/min/1.73 m
2
 in MM patients with RI.
62
 A small series 
of 14 patients with confirmed or presumed cast nephropathy treated with bortezomib, 
dexamethasone, and TPE reported normalization of serum creatinine in 43% of patients.
61
 A 
definitive answer on the role of TPE in MM patients with RI will require larger prospective 
trials with, for example, proteasome-inhibitor-based uniform pharmacological therapy. The 
removal of FLCs with dialysis is another method. The issue of whether an extended duration 
of dialysis with high cut off dialyzers is more effective than plasma exchange at removing 
FLCs or reversing renal failure is not established but should be solved in the near future and 
this method can also be combined with bortezomib or other anti-myeloma therapies.
63–65
 
Antimyeloma therapy in multiple myeloma patients with renal impairment 
High-dose chemotherapy with autologous stem cell transplantation (ASCT) may be 
performed in patients with severe RI or under dialysis using melphalan at a reduced dose (140 
mg/m
2
) albeit immediately reconstitution of RI is essential and ASCT may not always be 
readily applicable; therefore, immediate initiation of effective chemotherapies is 
recommended.
56
 Therapy with bortezomib-based regimens plus high-dose dexamethasone 
[either alone or with the addition of a third agent such as thalidomide (VTD), doxorubicin 
(PAD) or cyclophosphamide (VCD)] should be used as first choice.
56
 The prospective, 
randomized phase III (HOVON-65/GMMG-HD4) trial, including 81 of 827 patients with RI 
(serum-creatinine ≥2 mg/dL) and investigating PAD versus VAD followed by ASCT and 
maintenance with thalidomide or bortezomib, showed a substantial improved OS at three 
years for the patients with serum-creatinine of 2 mg/dL or more of 74% with PAD-ASCT-
  
bortezomib versus 34% with VAD-ASCT-thalidomide (P<0.001).
66
 In addition, it was also 
worthy of note that both OS and progression-free (PFS) survival were similar with base-line 
serum-creatinine of 2 mg/dL or more or less than 2 mg/dL in the PAD-ASCT-bortezomib 
arm. These results indicated that bortezomib-containing treatment before and after ASCT may 
overcome the negative prognostic impact of RI.
66
 In elderly or comorbid patients with RI, the 
combination with bortezomib with melphalan and prednisone (VMP) may be preferred.
67
 The 
second proteasome inhibitor which has been licensed for MM, carfilzomib, has also shown 
encouraging results in a small phase II study with 38 relapsed/refractory patients with RI (8 
on chronic dialysis); responses were similar among patients with different severity of renal 
dysfunction.
68
 More studies are needed to reveal the role of carfilzomib in RI. 
Immunomodulatory drugs (IMiDs) can also been administered in myeloma patients with RI. 
Thalidomide and lenalidomide are very effective especially in patients with mild to moderate 
RI; lenalidomide should be used with the recommended reduced doses based on renal 
function.
56,69
 Finally, responses to the combination of pomalidomide and low-dose 
dexamethasone were similar between patients with relapsed/refractory myeloma, irrespective 
of renal function.
70
 Bendamustine in combination with thalidomide or bortezomib and 
prednisone is also feasible and safe, even in patients with end-stage renal disease.
71,72
 
Analyses of newly diagnosed MM patients with at least moderate renal dysfunction showed 
that bortezomib-based regimens were the most effective in the reversibility of renal function. 
Time to major renal response (renalCR or renalPR) for thalidomide, bortezomib and 
lenalidomide-based regimes was 2, 1.12 and 1.25 months, respectively.
73
 
Recommendations: every myeloma patient with RI needs a thorough workup for the 
determination of the cause of RI (Figure 3). For the evaluation of RI, the MDRD formula is 
recommended in patients with stabilized serum creatinine. Patients with renal failure should 
be classified according to the KDIGO classification (grade 1B). Novel formulas, such as the 
CKD-EPI, with or without cystatin C, should be further assessed in clinical trials and in large 
patient cohorts to evaluate their utility and prognostic impact. Available data support the 
safety and efficacy of bortezomib-based therapies in MM patients with RI and thus 
bortezomib combined with dexamethasone (with or without thalidomide, doxorubicin or 
cyclophosphamide) is the recommended treatment (grade 1A). Lenalidomide is a feasible and 
effective therapy option with mild to moderate RI and is recommended with dose adjustment 
according to renal function (grade 1B). 
  
 
Figure 3. Algorithm for the initial workup of myeloma patients with renal impairment. 
 
Peripheral neuropathy 
Peripheral neuropathy (PN) is a significant complication of MM that can be caused by the 
disease itself or by certain therapies, including thalidomide- and bortezomib-based therapies. 
Thorough clinical evaluation has shown that up to 20% of MM patients have PN at diagnosis 
and up to 75% may experience treatment-emergent PN during therapy.
74
 MM-associated PN 
is primarily sensory or sensorimotor, and symptoms are predominantly symmetric, including 
paresthesia, numbness, burning sensation and weakness, often with mild intensity, but rarely 
with the potency to be inactivating or life-threatening. Treatment-induced PN symptoms are 
usually symmetric and distal with some differences among therapies.
75
 PN from thalidomide 
is cumulative, dose dependent and often permanent, and may also occur after treatment has 
already stopped.
74,75
 Bortezomib-induced PN is related to dose, schedule and mode of 
administration and is mostly reversible. Symptoms of bortezomib-induced PN may start 
distally and may progress proximally.
74,75
 A randomized trial of subcutaneous compared to 
intravenous administration of bortezomib showed a significant decrease in PN of all grades 
(38% vs. 53%) and grade 3 or 4 (6% vs. 16%) with the former, leading to its universal use.
76
 
  
Based on these data, the up-dated US prescribing information added that starting 
subcutaneous bortezomib may be considered for patients with pre-existing PN or at high-risk 
of PN (Table 3). The incidence of treatment-emergent PN with the newer proteasome 
inhibitors is relatively low. Experience from 526 relapsed/refractory MM patients in 4 phase 
II studies with carfilzomib reported an overall incidence of PN of 13.9%, grade 3 PN of 1.3% 
and no grade 4 or more; moreover all of the grade 3 PN occurred in patients with grade 1 or 2 
at baseline.
77
 
Table 2. Incidence of adverse events in multiple myeloma patients treated with different 
therapy regimens. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 3. Management of hematologic and non-hematologic complication in myeloma 
patients treated with novel agents 
 
 
 
 
Careful attention to the development of PN is essential, while patients are on therapy 
and prompt dose reductions are required. Lower doses of bortezomib, weekly 
administration or different schedules (4- instead of 3-week cycles) may also be used. 
Regular monitoring for treatment-emergent PN, sensible detection and intervention are 
relevant to prevent the development of more severe PN (Table 3).74,78 The NCI CTC 
definition of PN is commonly used in clinical routine, but should be used with 
neuropathy-specific patient-completed questionnaires, such as the whole or the reduced 
Total Neuropathy Score (Table 4).79 However, a need remains for more sensitive 
assessment tools that focus on MM patients with PN. 
 
  
Table 4. Total Neuropathy Scores. 
 
 
 
Several interventions have been investigated for treatment-induced PN, but prospective 
analyses are lacking. Acetyl-L-carnitin and alpha lipoic acid has shown activity in the 
treatment of chemotherapy-induced PN.
74
 Although the neuropathic pain may often be poorly 
responsive to standard analgesic treatment, opioids can be effective, which should be 
combined with other pain modulating drugs.
44,74
 In addition, calcium channel blocker (e.g. 
gabapentin and pregabalin), sodium channel blockers, such as oxcarbazepine and serotonin-
norepinephrine reuptake inhibitors (e.g. duloxetine) can be very effective, especially in 
painful PN.
44,74
 Recent studies in a mouse model with anti-TNF-α showed protection against 
neuropathy induced by bortezomib, but future studies are essential to elucidate the 
etiopathogenesis of neuropathy, the role of TNF-α pathway and how bortezomib differentially 
regulates NF-κB in tumoral and neuronal cells.80 
Recommendations: in the treatment for chemotherapy-induced PN, prevention is a key 
strategy for patients’ quality of life and ongoing treatment options (grade 2C). All MM 
patients with potential neurotoxic drugs should be routinely and clinically assessed for signs 
of PN before undergoing treatment; it is advisable that PN is graded with validated tools, 
such as the Total Neuropathy Score (grade 2C). The use for dose modifications for the 
management of bortezomib- or thalidomide-induced PN remains the ‘gold standard’ of care 
(grade 1C). Reduction of PN induced by bortezomib can be achieved by: a) prompt dose 
modification (1.3→ 1.0→ 0.7 mg/m2); b) once a week instead of twice weekly application; 
and c) subcutaneous rather than intravenous administration (Table 3). 
  
Infections 
Myeloma is associated with increased rate of infections, which is the main cause of death for 
myeloma patients. A recent population-based study on 9253 myeloma patients showed that 
the risk of developing a bacterial infection was 7-fold higher and for viral infections 10-fold 
higher compared to healthy individuals of the same sex and age. At one year of follow up, 
infection was the underlying cause in 22% of deaths in MM patients.
81
 Haemophilus 
influenzae, streptococcus pneumoniae, Gram negative bacilli and viruses (influenza and 
herpes zoster) are the most frequent causes of infection in myeloma patients.
81
 
The increased susceptibility of patients to infections results from the myeloma itself, therapies 
and/or age- and disease-related conditions. Myeloma-related innate immunodeficiency 
involves various parts of the immune system and includes B-cell dysfunction as well as 
functional abnormalities of dendritic-, T- and natural killer (NK)-cells.
82
 Myeloma- and 
treatment-associated organ dysfunction, such as renal and/or pulmonary impairment, 
alimentary mucosal damage and multiorgan involvement by myeloma-associated deposition 
disease also increase the risk for infections.
83
 Finally, MM affects older patients who 
frequently experience age-related frailty, geriatric conditions and physical dysfunctions 
making them more susceptible to infections (Figure 3).
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Multiple myeloma patients require thorough infection monitoring and appropriate use of 
antibiotics (Table 3).
85
 There are only a few prospective studies evaluating the role of 
prophylactic antibiotics in MM patients. In a randomized, phase II study in 157 patients who 
underwent ASCT, the administration of ciprofloxacin and vancomycin reduced the incidence 
of neutropenic fever, without affecting, however, the total interval of hospitalization, time to 
engraftment, or all-cause mortality.
86
 In another study, 212 myeloma patients who received 
initial chemotherapy were randomized on a 1:1:1 basis to daily ciprofloxacin (500 mg twice 
daily), trimethoprim-sulfamethoxazole (DS twice daily) or observation. The incidence of 
severe bacterial infections was similar among the three groups: 12.5%, 6.8% and 5.9%, 
respectively (P=0.218). Similarly, the incidence of any infection during the first two months 
of therapy was also comparable (20%, 23% and 22%, respectively; P=0.954).
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Regarding the incidence of infections with different therapies, this has been reported to be 
14% of patients treated with lenalidomide and dexamethasone in MM-009 and -010 trials
88
 
and approximately 30% (grade 3 and 4) of patients treated with pomalidomide plus low-dose 
dexamethasone, mainly during the first three months of therapy.
89
 For this reason, routine 
antibiotic prophylaxis should be considered for the first three months of therapy with these 
IMiDs and is particularly recommended for patients with aggressive disease, history of 
infectious complications or neutropenia.
88,89
 The available data do not support the use of any 
specific antibiotic regimen to use and thus clinicians should follow their institutional 
guidelines for antibiotic prophylaxis. In patients who receive pomalidomide, quinolones must 
be used with caution due to common metabolic pathways that can increase pomalidomide 
exposure. 
The use of prophylactic immunoglobulin replacement has shown no advantage in reducing 
infection rates in newly diagnosed myeloma patients.
90
 Regarding vaccinations, myeloma 
  
patients show suboptimal antibody responses to several vaccines; the responses seem to be 
worse for polysaccharide than protein antigens.
91
 In addition, all patients who undergo 
allogeneic SCT should receive vaccinations for Haemophilus influenzae type b, pertussis, 
pneumococci, meningococci, tetanus, diphtheria, hepatitis A and B, measles, mumps and 
rubella, influenza, poliomyelitis, varicella-zoster virus, human papilloma virus, and tick-borne 
encephalitis with a particular focus on vaccination of patients with active chronic graft-
versus-host disease (GvHD).
92
 
Recommendations: vaccination against influenza virus is appropriate and is recommended 
for both patients and their contacts. Moreover vaccination against Streptococcus pneumonia 
and Haemophilus influenzae is recommended, but efficacy for all vaccines is not guaranteed, 
due to suboptimal immune response (grade 1C). In general, live vaccines should be avoided 
in myeloma patients (grade 2C). Aciclovir or valacyclovir for herpes-zoster virus prophylaxis 
is recommended for patients receiving proteasome inhibitor-based therapies (grade 1A) or 
during ASCT/allogeneic-SCT, mainly in those with positive serology (grade 1C). Antiviral 
drugs should be continued for six weeks after discontinuation of the proteasome inhibitor. 
Due to increased infection rate during lenalidomide or pomalidomide administration, 
antibiotic prophylaxis is recommended at least for the first three months of therapy (grade 
2C). Prophylactic immunoglobulin replacement is not routinely recommended; however, it 
may be useful in a subset of patients with severe, recurrent bacterial infections and 
hypogammaglobulinemia (grade 2C). 
Venous thromboembolism 
Myeloma itself, antimyeloma therapies, the presence of infections, the history of previous 
venous thromboembolism (VTE), immobility, obesity, paraplegia, ESA treatment, 
comorbidities, dehydration and renal failure are all important factors for the development of 
VTE. The incidence of VTE is approximately 8–22/1000 person years. Disease-related risk 
factors include the hyperviscosity, the inhibition of natural anticoagulants and the 
hypercoagulability status induced by inflammatory cytokines (i.e. increased von Willebrand 
factor, fibrinogen and factor VIII levels, acquired activated protein C resistance, decreased 
protein S levels, etc.).
93
 The incidence of VTE during front-line therapy is 1%–2% with 
conventional therapies such as melphalan and prednisone, and it is doubled by the use of 
doxorubicin or other chemotherapeutic agents, while the use of IMiDs in combination with 
dexamethasone or chemotherapeutic agents produces a VTE risk of up to 70% in the absence 
of anticoagulation.
94
 The risk for a VTE is higher during the first four months of therapy with 
lenalidomide or pomalidomide and then seems to be reduced.
88,89
 Aspirin and low molecular 
weight heparin (LMWH) have been used in myeloma patients under IMiDs. In a prospective, 
randomized, study, which compared aspirin 100 mg/day and enoxaparin 40 mg/day in 342 
newly diagnosed patients who received lenalidomide and low-dose dexamethasone induction 
and melphalan-prednisone-lenalidomide consolidation, the incidence of VTE was 2.3% in the 
aspirin group and 1.2% in the enoxaparin group.
95
 Thus, aspirin can be considered as 
adequate anticoagulation therapy in patients who have no or one risk factor for VTE (i.e. 
hyperviscosity, personal or family history of VTE, obesity (Body Mass Index ≥30), co-
morbidities: cardiac, diabetes, RI, chronic inflammatory disease, immobility, thrombophilias, 
concomitant presence of myeloproliferative disorders, hemoglobinopathies, recent surgery 
  
(within 6 weeks), medications: ESAs, hormone replacement therapy, tamoxifen/stilboestrol, 
doxorubicin, high-dose steroids (≥480mg of dexamethasone/month). Otherwise LMWH or 
full-dose warfarin can be used. The risk for bleeding has also to be taken into account in the 
choice of anticoagulation.
94
 
Recommendations: patients who are due to start IMiD therapy should have a risk assessment 
for VTE and receive appropriate anticoagulation during the treatment duration (grade 1A). 
In these patients, aspirin (100 mg) is enough for VTE prophylaxis in low-risk patients (i.e. 
without risk factors, or only one myeloma/individual risk factor present), unless 
contraindicated (grade 1B). Otherwise, LMWH or full-dose warfarin has to be used (grade 
1B). The use of LMWH has to be continued for at least four months and then patients may be 
switched to aspirin prophylaxis (grade 2C). Treatment of confirmed VTE has to be according 
to international or national guidelines
96
 (grade 1A). In cases of VTE, despite the use of full 
anticoagulation, the treating physician should consider the discontinuation of the responsible 
anti-myeloma drug (grade 2C). 
Pain management recommendations 
Pain is a considerable problem for many patients with MM. Regarding bone disease, the use 
of BPs along with anti-myeloma therapy, radiation or balloon kyphosplasty in specific 
indications may control the pain of the patients. The treating physician should take into 
account that, in several patients, pain, and especially back pain, may be due to other reasons, 
and not to myeloma itself. Regarding the relief of pain using pain killers or other drugs, on the 
basis of available data we suggest the following.
97–100
 Paracetamol can be administered at a 
dose of up to 1 g qid for the control of mild pain (grade 1B). In general, non-steroidal anti-
inflammatory drugs should be avoided in MM (grade 2C). Oral tramadol or codeine can be 
given for the control of mild-moderate pain (grade 1C). In cases of chronic moderate to severe 
pain, fentanyl or buprenorphine patches or oxycodone are recommended (grade 1B). For 
severe chronic pain, nervous block with anesthetic drugs can be performed, while neurolytic 
block using chemicals, heat and freezing, may produce long-lasting blockade with pain relief 
for weeks, months or indefinitely. For the management of acute severe pain, subcutaneous 
opioid (i.e. oxycodone or morphine injection) can be used for the rapid relief of symptoms 
(grade 2B). Patients on opioids should be also given laxatives (grade 1A). All patients with 
chronic pain may be also considered as candidates for calcium channel blockers (gabapentin 
or pregabalin), for sodium channel blocker (lidocaine, oxcarbazepine) or a serotonin-
norepinephrine reuptake inhibitors (duloxetine or amitryptiline) (grade 1B). 
Conclusion 
In conclusion, complications related to disease and/or anti-myeloma drugs contribute to 
increased mobility and mortality of myeloma patients. Furthermore, such complications also 
alter the performance status of the patients to define fit versus frail patients and consequently 
select and/or dose-reduce therapy (Figure 4). Therefore, the appropriate management of these 
complications is crucial for both patient quality of life and survival, and treating physicians 
must pay special attention to their management. 
  
 
 
Figure 4. Special considerations prior to therapy in elderly or frail patients. In multiple myeloma patients with 
newly diagnosed or refractory disease a detailed geriatric and functional assessment helps to define more 
precisely ‘fit’ versus ‘frail’ patients and to evaluate patients’ risk for treatment toxicity and treatment 
discontinuation. These definitions of fit, unfit and frail patients are anticipated to influence selection of 
therapeutics, as well as the correct allocation to intensive or non-intensive treatment should reduce side-
effects/SAEs and treatment toxicity. 
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